Literature DB >> 21635195

Anticoagulation prescription in atrial fibrillation.

Vicente Bertomeu-González1, Alberto Cordero, Pilar Mazón, José Moreno-Arribas, Lorenzo Fácila, Julio Nuñez, Moisés Rodríguez-Mañero, Juan Cosín-Sales, Jose Ramón González-Juanatey, Juan Quiles, Vicente Bertomeu-Martínez.   

Abstract

AIMS: We seek to assess the factors associated with the anticoagulation prescription in a cohort of patients with atrial fibrillation (AF) collected from out-patient clinics.
METHODS: A total of 1524 patients with a history of AF were collected from out-patients clinics. CHADS(2), CHA(2)DS(2)-VASc and HAS-BLED scores were calculated in every patient. Variables associated with anticoagulant treatment prescription were analyzed in univariant and multivariant models.
RESULTS: Most patients received either anticoagulant (62%) or antiplatelet treatment (37%). Anticoagulation rates increased among higher CHADS(2) and CHA(2)DS(2)-VASc score values. A logistic regression model was performed to assess the variables associated with the prescription of anticoagulant treatment; the variables with stronger association were the presence of arrhythmia at the current visit (odds ratio (OR) 33, 95% CI 27-40, p<0.001) and lack of concomitant antiplatelet treatment (OR 0.17, 95% CI 0.14-0.21, p<0.001).
CONCLUSIONS: Although prognosis of patients with AF is mainly determined by the long-term thrombotic risk, the prescription of antithrombotic therapy depends more on the bleeding risk and the immediate thrombotic risk perception.
© 2011 Informa UK, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21635195     DOI: 10.1517/14656566.2011.584063

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  2 in total

Review 1.  Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis.

Authors:  Jing-Tao Zhang; Ke-Ping Chen; Shu Zhang
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

2.  Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database.

Authors:  Maria Giner-Soriano; Cristina Vedia Urgell; Albert Roso-Llorach; Rosa Morros; Dolors Capellà; Xavier Castells; Ignacio Ferreira-González; Amelia Troncoso Mariño; Eduard Diògene; Josep M Elorza; Marc Casajuana; Bonaventura Bolíbar; Concepció Violan
Journal:  BMJ Open       Date:  2016-01-28       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.